09:49 AM EST - Aeterna Zentaris Inc. : reported final results on the clinical activity of perifosine or KRX-0401, in combination with capecitabine or Xeloda as a treatment for advanced, metastatic colorectal cancer. The primary endpoint of this study was to measure Time to Progression. The P-CAP arm demonstrated a statistically significant advantage for TTP and OS, as well as for the percentage of patients achieving Stable Disease or better lasting 12 or more weeks, as compared to the CAP arm. The P-CAP arm demonstrated a greater than 60% improvement in OS, a more than doubling of median TTP, and almost a doubling of the percentage of patients achieving SD or better. The P-CAP arm again demonstrated a statistically significant increase in both TTP and OS compared to the CAP arm. Aeterna Zentaris Inc.
shares T.AEZ are trading up $0.02 at $1.64.
